Kb Financial Partners, LLC Incyte Corp Transaction History

Kb Financial Partners, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 16, 2023	SELL	$70.23 - $86.01 $842 - $1,032	-12 Reduced 0.27%	4,467 $323,000
Q4 2022 Feb 17, 2023	BUY	$67.18 - $84.11 $738 - $925	11 Added 0.25%	4,479 $360,000
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $50,362 - $63,056	761 Added 20.53%	4,468 $298,000
Q2 2022 Aug 11, 2022	SELL	$66.18 - $83.18 $67,834 - $85,259	-1,025 Reduced 21.66%	3,707 $282,000
Q1 2022 May 17, 2022	BUY	$66.02 - $79.71 $32,151 - $38,818	487 Added 11.47%	4,732 $376,000
Q4 2021 Feb 18, 2022	SELL	$63.34 - $74.11 $198,380 - $232,112	-3,132 Reduced 42.46%	4,245 $312,000
Q3 2021 Nov 16, 2021	BUY	$68.67 - $84.02 $117,837 - $144,178	1,716 Added 30.31%	7,377 $507,000
Q2 2021 Aug 17, 2021	BUY	$79.87 - $87.53 $190,410 - $208,671	2,384 Added 72.75%	5,661 $476,000
Q1 2021 Jun 08, 2021	BUY	$76.02 - $100.5 $249,117 - $329,338	3,277 New	3,277 $266,000

642

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.8B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Kb Financial Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Kb Financial Partners, LLC with notifications on news.